Board of Directors
Interim Chief Executive Officer
Gary H. Rabin, 53, has a 32-year career in finance, investing, biotechnology management, and financial restructuring. He has been the Managing Member of Vine Holdings Group since 2015. Previously he was the Chairman and CEO of Advanced Cell Technology, Inc., a biotechnology company in the cell therapy industry, where he led a successful financial turnaround. He has also been the portfolio manager of three hedge funds in the tech/media/telecom sector. From 1987 until 2002, he was a media and telecom investment banker for some of the world’s largest investment banking firms including CIBC, ING Barings, UBS and First Boston.
Daniel Kazado is a Senior Advisor to Melini Capital, a family owned private and public equity firm investing internationally in several industries. Melini Capital has been an early and significant investor in Immune Pharmaceuticals. Daniel built his own management consulting firm over 15 years to 25 professionals advising boards of directors and senior management in multiple industries, and in 2002 sold the company to Altran Technologies, a global engineering and management consulting group with revenues of over 1 billion. Daniel earned a bachelor's degree in Business Administration and a master's degree in Management from Lyon University in France.
Jeff Paley, MD
Dr. Jeff Paley has been an Active Clinician and Consultant in the healthcare industry for the past 19 years, during which time he has consulted for over 30 analysts and portfolio managers in the biotechnology, pharmaceutical, specialty pharmaceutical and medical technology arenas, reviewing the clinical, preclinical and regulatory pedigrees of numerous therapeutics and devices. Dr. Paley has also consulted for several biotechnology and specialty pharmaceutical companies, most notably in the areas of clinical development and business development and he has engineered transactions worth over $600 MM. Dr. Paley founded Access Medical Associates in 2003, after spending five years on the full-time academic faculty of Weill Cornell Medical College, where he served as a Director of Clinical Research at the Cornell Internal Medicine Associates. At Weill Cornell, Dr. Paley was a Principal or Co-Principal Investigator on several studies of diabetes, hypertension, and cholesterol disorders, including the landmark ACCORD study of intensive hyperglycemia, hypertension and hyperlipidemia management. He has served as a Director of Kellbenx and Retrophin and currently serves as a Director of Kalytera, Avenue Therapeutics and Remote Radiology Inc. Dr. Paley trained at Harvard Medical School and completed a residency in Internal Medicine at Massachusetts General Hospital.
John Neczesny, MBA
Mr. Neczesny brings over 28 years of investment banking and corporate experience to this role. Mr. Neczesny is a Managing Partner at Blue Ox Healthcare Partners, LLC, a private investment firm providing capital to growth-stage healthcare companies. He was previously a Managing Director at Oberon Securities, LLC as an investment banker to healthcare companies and Vice President, Corporate Development at Par Pharmaceutical Companies. From 1998 to 2008, Mr. Neczesny was an investment banker at Bear Stearns & Co. Inc. in the Healthcare group, where he rose to Managing Director and was involved in numerous M&A and capital markets transactions for pharmaceutical, biotechnology and medical technology companies. Prior to his corporate finance career, he spent 9 years in business development and project management roles in contract laboratory and data management businesses. Mr. Neczesny earned an MBA in Finance from New York University Stern School of Business and a Bachelor of Science degree in Chemistry from the University of Delaware.
Tony Fiorino, MD, PhD
Dr. Fiorino served as Immune's Interim CEO from August 2018 through March 2019, and before that was the Company's CMO and COO from August 2017. He joined Immune from Triumvira Immunologics, an immuno-oncology company developing a novel engineered T cell platform, where he served as President and Chief Executive Officer. Prior to joining Triumvira, Dr. Fiorino was the Chief Executive Officer of BrainStorm Cell Therapeutics (NASDAQ: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases. During his tenure, BrainStorm conducted a phase 2 trial of neurotrophic factor-secreting mesenchymal stem cells in amyotrophic lateral sclerosis, raised $25 million in equity capital, and uplisted to the NASDAQ. Prior to joining BrainStorm, he was the Founder, President and CEO of EnzymeRx, where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through phase 2 clinical trials and its subsequent sale to 3SBio. Before founding EnzymeRx, Dr. Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup, and Pequot Capital. Dr. Fiorino earned an MD and a PhD from the Albert Einstein College of Medicine, where he studied the differentiation of liver progenitor cells, and a BS from the Massachusetts Institute of Technology.